SFI
PLRX icon

Susquehanna Fundamental Investments’s Pliant Therapeutics PLRX Stock Holding History

Susquehanna Fundamental Investments’s Portfolio PLRX Stock Details PLRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-11,936
Closed -$201K – 1697
2021
Q3 		$201K Buy
+11,936
New +$253K ﹤0.01% 1539

Other funds holding PLRX

TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
HMC
Harvard Management Company Boston, Massachusetts $1.82B AUM 26.23% 1-Year Est. Return

Susquehanna Fundamental Investments's PLRX Position: Q4 2021 in Review

Susquehanna Fundamental Investments sold out of Pliant Therapeutics (PLRX) in Q4 2021, closing a stake of 11,936 shares — an estimated $201K sold.

Susquehanna Fundamental Investments first reported a position in PLRX in Q3 2021 and held it in 1 quarter. The position peaked at $201K in Q3 2021. 88 funds tracked by Wall St. Rank hold PLRX as of Q4 2021.

  • Susquehanna Fundamental Investments reported no remaining Pliant Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Susquehanna Fundamental Investments sold 11,936 Pliant Therapeutics shares in Q4 2021, an estimated $201K.
  • Susquehanna Fundamental Investments first reported a position in Pliant Therapeutics in Q3 2021 and held it in 1 quarter.
  • Susquehanna Fundamental Investments's Pliant Therapeutics position peaked at $201K in Q3 2021.
  • 88 funds tracked by Wall St. Rank held Pliant Therapeutics as of Q4 2021.

Based on Susquehanna Fundamental Investments's 13F filing for Q4 2021, filed 14 Feb 2022.